β-Methoxy-2,5-dimethoxy-4-bromoamphetamine (β-MeO-DOB), also known by its developmental code name AL-37662, is an experimental putative psychedelic drug which has a markedly reduced ability to cross the blood-brain barrier. The compound was developed and evaluated as a peripheral agent for topical application (in the form of eye drops) with the aim of reducing intraocular pressure in glaucoma.
Pharmacology Pharmacodynamics AL-37662 acts as a full 5-HT2A receptor agonist with an affinity (Ki) of 0.3nM; it successfully reduced intraocular pressure by 20 to 27% when administered topically. If administered directly into the brain or taken by any means other than as eye drops in high doses, it may cause psychedelic effects; however, when administered as therapeutic eye drops in microdoses (300 µg), AL-37662 did not produce any effects.
History AL-37662 was first described in the scientific literature by Richard Glennon and colleagues in 2004.
See also BOx (psychedelics) BOB (β-methoxy-2C-B)
References
External links β-MeO-DOB - Isomer Design